Envoy Medical, Inc. (COCH) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2022
Loading P/E history...
COCH Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Envoy Medical, Inc. (COCH) trades at a price-to-earnings ratio of -0.5x, with a stock price of $0.66 and trailing twelve-month earnings per share of $-1.21.
The current P/E is 101% below its 5-year average of 73.4x. Over the past five years, COCH's P/E has ranged from a low of 39.4x to a high of 107.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, COCH trades at a 102% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, COCH trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our COCH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
COCH P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 26.7 | - | -22% | |
| $100B | 21.6 | - | +31% | |
| $151B | 11.4 | 0.38Best | +134% | |
| $84B | 29.2 | - | +55% | |
| $23B | 47.3 | 5.72 | +2% | |
| $3B | 30.4 | 6.91 | -15% | |
| $13B | 91.7 | 48.97 | +169% | |
| $5B | 92.7 | 28.13 | -17% | |
| $2B | 6.9Lowest | 0.67 | +817%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
COCH Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q2 | $9.80 | $0.09 | 107.5x | +46% | |
| FY2022 Q1 | $9.77 | $0.25 | 39.4x | -46% |
Average P/E for displayed period: 73.4x
See COCH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COCH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COCH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCOCH — Frequently Asked Questions
Quick answers to the most common questions about buying COCH stock.
Is COCH stock overvalued or undervalued?
COCH trades at -0.5x P/E, below its 5-year average of 73.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does COCH's valuation compare to peers?
Envoy Medical, Inc. P/E of -0.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is COCH's PEG ratio?
COCH PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2022.